SecBot SecBot
SECBOTREPLAY Home › Report › HCM

HCM · HUTCHMED (HCM) announces conditional NMPA approval in China for…

HUTCHMED (China) Ltd · 6-K filed Jul 2, 2026 at 06:08 ET

At the news

BULLISHIMPACT 7/10

6-K filed Jul 2, 2026 at 06:08 ET

HUTCHMED (HCM) announces conditional NMPA approval in China for ORPATHYS (savolitinib) to treat MET-amplified advanced gastric or gastroesophageal junction adenocarcinoma in patients who have failed at least two prior systemic treatments. This is the third approved indication for ORPATHYS in China, supported by a pivotal Phase II study showing a 32.3% objective response rate, and the drug is already on the National Reimbursement Drug List for its prior lung cancer indication, providing a clear commercial path alongside partner AstraZeneca.

  • ORPATHYS (savolitinib) received conditional NMPA approval for MET-amplified advanced GC/GEJ adenocarcinoma after >=2 prior systemic treatments
  • Approval supported by Phase II study (NCT04923932): IRC-assessed ORR 32.3% (95%CI: 21.2%-45.1%), DCR 63.1%, median DoR 9.7 months, median PFS 4.0 months
  • Estimated annual incidence of MET-amplified gastric cancer in China is ~18,000 patients (~4-6% of all gastric cancer cases)
  • This is the third approved indication for ORPATHYS in China; it is already on the NRDL (since March 2023) for prior lung cancer indication

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access